Business Details
38 Years
experience
Pioneering Biotechnology for Life-Changing Medicines
Regeneron Pharmaceuticals is a pioneering biotechnology company dedicated to transforming scientific discovery into life-changing medicines. Founded on a foundation of rigorous scientific research and innovation, we specialize in developing cutting-edge therapies for serious diseases through proprietary technologies like our VelociSuite platforms. With over 35 years of leadership in genetics, biology, and drug development, we combine deep expertise with a commitment to ethical practices and global health impact.Our team of physician-scientists and Nobel Laureates drives advancements in antibody research, genetic medicines, and cell therapies, ensuring patients worldwide gain access to groundbreaking treatments. Through strategic collaborations and a relentless focus on quality, Regeneron Pharmaceuticals continues to redefine the boundaries of medical science.
Services
Genetic Medicine Development
Antibody Research
Clinical Trials
Drug Discovery Platforms
Biologics Manufacturing
Genomic Research
Cell Therapy Development
Rare Disease Treatment
mRNA Therapeutics
Targeted Enzyme Replacement
Details
- Year established: 1988
Highlights and features
- We offer over 35 years of leadership in biotechnology innovation.
- Our proprietary VelociSuite technologies accelerate drug discovery and development.
- We maintain a 100% in-house pipeline for therapeutic consistency.
- Our team includes Nobel Laureates and National Academy of Sciences members.
- We prioritize ethical practices in global clinical trials and manufacturing.
Services
Genetic Medicine Development
Regeneron Pharmaceuticals advances genetic medicines using CRISPR technology and viral vectors to target rare diseases. Our approach combines antibody delivery with gene editing for precise tissue targeting. With over 45 product candidates in development, we focus on conditions like hemophilia and neurological disorders through innovative delivery mechanisms.
Antibody Research
Our VelociImmune platform produces fully human monoclonal antibodies for treating cancer and autoimmune diseases. This technology enables rapid development of therapies like Dupixent and Libtayo through genetically humanized mouse models. We maintain industry-leading production efficiency with 100% in-house pipeline control.
Clinical Trials
We conduct global clinical trials across 60+ countries with a patient-centric approach. Our trials utilize real-world data from 3M+ sequenced exomes to identify genetic markers. The process emphasizes safety, efficacy, and accelerated approval pathways for critical therapies like Evkeeza and Praluent.
Drug Discovery Platforms
Our VelociSuite platforms (Gene, Mouse, Mab, Bi) enable high-throughput drug discovery. These technologies reduce development timelines by 30-50% through automated target validation and bispecific antibody generation. We've produced 14 FDA-approved medicines using these integrated systems.
Biologics Manufacturing
Regeneron Pharmaceuticals's Industrial Operations team ensures large-scale production of monoclonal antibodies and fusion proteins. We maintain cGMP compliance across global facilities with proprietary EESYR and FASTR technologies enhancing protein yield by 40%. Quality control includes 100% batch traceability and stability testing.
People
Leonard S. Schleifer
Board Co-Chair, President and CEO
Dr. Schleifer co-founded Regeneron Pharmaceuticals in 1988 and has led its transformation into a top-tier biotech company. His vision combines clinical expertise with business strategy, driving 14 FDA approvals and 35+ years of scientific leadership.
George D. Yancopoulos
Board Co-Chair, President and CSO
Dr. Yancopoulos invented key technologies including VelociImmune, revolutionizing antibody drug development. As chief scientist, he oversees platform innovations that have produced 10+ blockbuster therapies through his 30+ years of technical leadership.
Aris Baras
Head of Regeneron Genetics Center
Dr. Baras directs the RGC's 3M+ exome sequencing initiative, identifying novel drug targets through population genetics. His team's work has directly contributed to 12+ clinical programs by linking genetic variants to disease mechanisms since joining in 2011.
Philip Gregory
Senior Vice President, Cell Medicines
Dr. Gregory leads Regeneron Pharmaceuticals's cell therapy expansion following the 2024 acquisition of 2seventy bio. With 25+ years in gene therapy development, he integrates CAR-T technologies with existing biologics expertise to create next-gen cancer treatments.
Ned Braunstein
Executive Vice President, Regulatory Affairs
Dr. Braunstein oversees global regulatory strategy with 30+ years of experience in clinical development. He has secured approvals for 8+ major therapies by navigating complex regulatory pathways across FDA, EMA, and PMDA jurisdictions.
Questions
What areas of medicine does Regeneron Pharmaceuticals focus on?
We focus on eye diseases, allergic/inflammatory conditions, cancer, cardiovascular/metabolic disorders, neurological diseases, rare diseases, and genetic medicines.
How does Regeneron Pharmaceuticals develop new therapies?
We use proprietary VelociSuite technologies for antibody discovery, CRISPR-based gene editing, and mRNA platforms to accelerate drug development.
Are Regeneron Pharmaceuticals's medicines available globally?
Yes, our FDA-approved medicines are available in over 100 countries worldwide through strategic distribution partnerships.
How can patients participate in clinical trials?
Patients can explore active trials on our website or contact our medical information team for enrollment details.
What sustainability initiatives does Regeneron Pharmaceuticals have?
We've achieved 100% landfill waste diversion and prioritize eco-friendly manufacturing processes across global operations.
Videos
